The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma
In this video, Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, presents some preliminary findings from a sub-study of the DREAMM-5 platform trial (NCT04126200), which analyzed the safety and efficacy of the antibody-drug conjugate belantamab mafodotin (belamaf) in combination with feladilimab, an inducible T-cell co-stimulatory agonist (aICOS) in patients with relapsed/refractory (R/R) myeloma. Dr Callander highlights some of the results of this sub-study, including the overall and partial response rates observed in patients. To conclude, Dr Callander compares some safety signals in this sub-study with those observed in the DREAMM-2 trial (NCT03525678), drawing focus on the incidence of keratopathy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
